The difference between Anavex and NWBO is vast.
Anavexs lead compound, 2-73, is small molecule that is easily manufactured. CEO Chris Missling once stated they already had enough 2-73 in stock-pile to dose (the whole of Manhattan) . It will be relatively cheap as well and most insurance's will cover it...cost is between $25-40k per year, depending on dose size. Alzheimer's is also a HUGE money maker the market potential is enormous vs. NWBO DCvax is very difficult to make and very expensive.
You also cant compare how AVXL is run vs NWBO. Missling vs Powers = Missling had a plan early on to raise cash and OS are only a bit above 82M vs 1.4B for NWBO. Anavex has a cash runway for 3+ years, vs day by day for NWBO. Missling is also very transparent and Company plans are communicated, in detail for the msot part to its shareholders and Wall Street. Missling also got Anavex added to the Russel, which was huge in terms of being added to Index and Mutual Funds. NWBO has poorly executed its business strategy, and I would argue they truly dont really have one, or if they do, they cant seem to execute it because they just dont have what it takes.
One thing is for sure...if Anavex receives approval from the current application for Alz in the EU...the stock is most likely going over $100. If NWBO receives approval for DCvax in the the UK, we may see .75-$1. The market is just to small to command much more than that in terms of market cap. No NICE appraisal and not FDA filing will be a HUGE detriment to SP upside.
Sorry for any typos, getting ready for my daughters hockey game.
Market Data 
Markets 
AI
